Results 161 to 170 of about 578,179 (195)

Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Hetta HF, Salama A, Aljuaid TA, Mojmami YT, Alotibi RS, Alqabaly AM, Aldosari NA, Alshahri SA, Asiri WIA, Alamri RS, Alanazi FA, Alenazi MSA, Albuhayri MH, Ramadan YN, Sayad R.   +14 more
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres. [PDF]

Transl Oncol
Jo E, Lee E, Oh Y, Lee D, Lee B, Kim K, Choi RJ, Hong J, Jeon Y, Cho H, Choi YS, Kim S, Won SY, Choi S, Roh TH, Moon JH, Kim EH, Chang JH, Jeon R, Kang SG.   +19 more
europepmc   +1 more source

Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View. [PDF]

Mediterr J Hematol Infect Dis
Molica S, Allsup D.
europepmc   +1 more source

The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors. [PDF]

Front Immunol
Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung HP, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C.   +12 more
europepmc   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

Discovery of Reversible, Noncovalent Bruton's Tyrosine Kinase Inhibitors Targeting BTK C481S Mutation. [PDF]

ACS Med Chem Lett
Das D, Xie L, Qiao D, Cao Y, Jiang S, Zheng M, Liu Z, Li Y, Jia J, Lv Y, Hong J.   +10 more
europepmc   +1 more source

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]

Front Oncol
Kluitmans DJF, Melis JJTM, van den Bossche E, Ytsma J, de Roos JADM, van Linden OPJ, Grobben Y, Kooijman JJ, Zaman GJR.   +8 more
europepmc   +1 more source

In Silico Molecular Docking Analysis of Valproic Acid as an Inhibitor of Bruton's Tyrosine Kinase: Potential Drug Repurposing for Allergies. [PDF]

Cureus
Martinez-Martinez RE, Calva-Hernandez CI, Rodriguez-Lopez GM, Soria-Castro R, Ruiz-Sanchez BP, Chavez-Blanco AD, Pérez-Tapia SM, Pavano-Rodriguez CG, Chacon-Salinas R.   +8 more
europepmc   +1 more source